Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 5OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 265Leukemia 183Carcinoma, Non-Small-Cell Lung 168Lymphoma 159Lung Neoplasms 148Prostatic Neoplasms 134Precursor Cell Lymphoblastic Leukemia-Lymphoma 130Ovarian Neoplasms 117Colorectal Neoplasms 115Sarcoma 108Central Nervous System Neoplasms 107Head and Neck Neoplasms 98Leukemia, Myeloid, Acute 95Multiple Myeloma 93Squamous Cell Carcinoma of Head and Neck 83Rectal Neoplasms 77Colonic Neoplasms 71Uterine Cervical Neoplasms 65Neoplasm Metastasis 65Neuroblastoma 64Carcinoma, Ovarian Epithelial 64Brain Neoplasms 64Neoplasms 63Fallopian Tube Neoplasms 62Lymphoma, Large B-Cell, Diffuse 61Astrocytoma 59Melanoma 58Leukemia, Lymphocytic, Chronic, B-Cell 56Burkitt Lymphoma 56Hodgkin Disease 55

Interventions

Docetaxel 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Metastatic Hormone-sensitive Prostate Cancer × Clear all
NCT00309985 2025-12-11

CHAARTED

Eastern Cooperative Oncology Group

Phase 3 Completed
790 enrolled 11 charts
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡